Literature DB >> 12420198

Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements.

G S Stergiou1, S P Efstathiou, I I Skeva, N M Baibas, C B Kalkana, T D Mountokalakis.   

Abstract

This study investigated the differences in the effect of an angiotensin converting enzyme inhibitor (ACEI) compared with an angiotensin receptor blocker (ARB) on blood pressure (BP) and pulse pressure (PP) measured in the clinic (CBP and CPP, respectively), at home (HBP, HPP) and with ambulatory monitoring (ABP, APP). Twenty-seven hypertensive patients were randomised to receive lisinopril (20 mg) or losartan (50 mg) for 5 weeks, and were subsequently crossed-over to the alternative treatment for a second 5-week period. Measurements of CBP, 24-h ABP and 5-days HBP were performed before randomisation and at the end of each treatment period. All measurement methods showed that lisinopril was more effective than losartan in reducing BP. However, the difference between the two drugs was demonstrated with greater precision using HBP (P<0.001) than 24-h ABP (P<0.01), whereas the poorest precision for demonstrating this difference was provided by CBP (P<0.05). Lisinopril was also found more effective than losartan in reducing HPP (P=0.01) and 24-h APP (P=0.03) whereas no such a difference was detected using measurements of CPP. It was concluded that the antihypertensive drugs may differ in their effects not only on BP, but also on PP. HBP monitoring appears to be as reliable as 24-h ABP monitoring in detecting differences in the effect of drugs on both BP and PP. Clinic measurements seem to be the least reliable method, particularly in the detection of differences in PP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12420198     DOI: 10.1038/sj.jhh.1001477

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

1.  Changes in home versus clinic blood pressure with antihypertensive treatments: a meta-analysis.

Authors:  Joji Ishikawa; Deirdre J Carroll; Sujith Kuruvilla; Joseph E Schwartz; Thomas G Pickering
Journal:  Hypertension       Date:  2008-09-22       Impact factor: 10.190

2.  Compliance with home blood pressure monitoring among middle-aged Korean Americans with hypertension.

Authors:  Jiyun Kim; Hae-Ra Han; Heejung Song; JongEun Lee; Kim B Kim; Miyong T Kim
Journal:  J Clin Hypertens (Greenwich)       Date:  2010-04       Impact factor: 3.738

Review 3.  Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis.

Authors:  Harikrishna Makani; Sripal Bangalore; Azhar Supariwala; Jorge Romero; Edgar Argulian; Franz H Messerli
Journal:  Eur Heart J       Date:  2013-08-21       Impact factor: 29.983

4.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

5.  Ten-year changes in ambulatory blood pressure: The prognostic value of ambulatory pulse pressure.

Authors:  Paolo Balietti; Francesco Spannella; Federico Giulietti; Giulia Rosettani; Beatrice Bernardi; Guido Cocci; Anna R Bonfigli; Riccardo Sarzani
Journal:  J Clin Hypertens (Greenwich)       Date:  2018-07-07       Impact factor: 3.738

Review 6.  Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy.

Authors:  Christoph Schindler; Peter Bramlage; Wilhelm Kirch; Carlos M Ferrario
Journal:  Vasc Health Risk Manag       Date:  2007

Review 7.  The applicability of home blood pressure measurement in clinical practice: a review of literature.

Authors:  Willem J Verberk; Abraham A Kroon; Heidi A Jongen-Vancraybex; Peter W de Leeuw
Journal:  Vasc Health Risk Manag       Date:  2007
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.